IL-27 and downstream mechanisms in Alopecia Areata

斑秃中的 IL-27 及其下游机制

• 批准号: 10297577
• 负责人: Ali Jabbari
• 金额: $ 33.99万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-09-17 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10297577
• 关键词: 20 year old; Address; Adopted; Adoptive Transfer; Affect; Alopecia Areata; Anti-Inflammatory Agents; Antigen-Presenting Cells; Antiinflammatory Effect; Autoimmune; Autoimmune Diseases; Autoimmune Responses; Autoimmunity; Automobile Driving; Blocking Antibodies; Bone Marrow; CD8-Positive T-Lymphocytes; CD8B1 gene; Cells; Cellular biology; Clinical; Data; Dependovirus; Development; Disease; Endothelial Cells; Epithelial; Epithelial Cells; Equilibrium; FDA approved; Familiarity; Foundations; Gene Expression; Genetic; Goals; Hair; Hair follicle structure; Immune; Immune Targeting; Immune response; Immune system; Infiltration; Inflammatory; Interleukin-10; Knowledge; Lead; Ligands; Ligation; MHC Class I Genes; MHC Class II Genes; Maintenance; Mediating; Medical; Modeling; Molecular; Mus; Organ; Outcome; Participant; Pathogenesis; Pathogenicity; Pathway interactions; Patients; Pharmaceutical Preparations; Phenotype; Population; Production; Property; Quality of life; Regulatory T-Lymphocyte; Research; Role; Signal Pathway; Signal Transduction; Site; Skin; T cell differentiation; T cell response; T-Lymphocyte; Therapeutic Agents; Therapeutic Uses; Tissues; United States; Up-Regulation; Work; autoimmune pathogenesis; autoreactive T cell; base; cell type; cytokine; draining lymph node; effector T cell; immunoregulation; improved; in vivo; interleukin-10 receptor; lifetime risk; mortality; mouse model; new therapeutic target; novel strategies; novel therapeutic intervention; overexpression; preservation; prevent; psychosocial; receptor; self esteem; side effect; tool; transcriptomics; tumor

PROJECT SUMMARY Alopecia areata (AA) is a common autoimmune disease in which the hair follicle is the target of attack and results clinically in hair loss. Despite the associated high lifetime risk of approximately 2% and its substantive psychosocial impact, no FDA approved treatments exist for AA. The lack of effective options for the population that suffers from this disfiguring disease with significant psychosocial ramifications represents a significant unmet medical need. The absence of approved treatments is in part due to an incomplete understanding of the unbalanced equilibrium between pathogenic immune responses and immunoregulatory mechanisms that prevent autoimmunity in AA. Although many cytokines, pathways, and cell types have been hypothesized to prevent immune attack of the hair follicle, it is unknown what factors participate in regulating autoimmune responses in vivo. Identifying these critical immunoregulatory participants may not only deepen our understanding of AA pathogenesis, but may reveal anti-inflammatory pathways that may be exploited to develop novel approaches to treatment. IL-27 is a cytokine with immunoregulatory properties that has been studied in various autoimmune, infectious, and tumor models. The receptor for IL-27 is expressed by a wide array of immune cell types as well as epithelial and endothelial cells, supporting its potential to modulate the immune system and critical cell types that interact with the immune system. In particular, IL-27 has been shown to dampen conventional T cell responses, increase the number of regulatory T cells, and induce naïve and previously activated CD4 and CD8 T cells to produce IL-10, a well-known cytokine with anti-inflammatory effects in most contexts. Our preliminary data indicate that overexpression of IL-27 can substantially prevent the development of murine AA, and further analysis revealed regulatory T cells and IL-10 as potential downstream candidates participating in disease suppression. We propose to study the mechanisms of AA suppression of exogenous IL-27 and its downstream effects on regulating immune responses to the hair follicle and preventing the development of AA. We have adopted and further developed a spontaneous AA mouse model to robustly develop disease in an inducible, controlled, and well-characterized manner by adoptive transfer of activated pathogenic T cells. Combining our AA model with newly developed genetic tools will allow us to dissect the mechanisms by which IL-27 may be used to ablate AA pathogenesis and has the potential to reveal novel therapeutic strategies.

项目总结 斑秃是一种常见的自身免疫性疾病，毛囊是其攻击的目标。 并在临床上导致脱发。尽管相关的高终生风险约为2%，而且其实质性 心理社会影响，没有FDA批准的AA治疗方法。人口缺乏有效的选择 患有这种具有重大心理社会分支的毁容疾病的人代表着一种重大的未满足的 医疗需要。 没有得到批准的治疗方法的部分原因是对不平衡的 病原性免疫反应和免疫调节机制之间的平衡 再生障碍性贫血的自身免疫性。尽管许多细胞因子、途径和细胞类型被认为可以防止 毛囊的免疫攻击，目前尚不清楚有哪些因素参与调节自身免疫反应 活着。确定这些关键的免疫调节参与者不仅可以加深我们对再生障碍性贫血的理解 发病机制，但可能揭示抗炎途径，可被利用来开发新的方法 治疗。 IL-27是一种具有免疫调节特性的细胞因子，已被研究在各种自身免疫中， 感染性和肿瘤模型。IL-27的受体也由多种免疫细胞类型表达 作为上皮细胞和内皮细胞，支持其调节免疫系统和关键细胞的潜力 与免疫系统相互作用的类型。特别是，IL-27已经被证明可以抑制传统的T细胞 应答，增加调节性T细胞的数量，并诱导幼稚的和先前激活的CD4和CD8 T细胞产生IL-10，这是一种在大多数情况下具有抗炎作用的众所周知的细胞因子。我们的 初步数据表明，IL-27的过表达可以实质上阻止小鼠再生障碍性贫血的发展， 进一步的分析显示，调节性T细胞和IL-10是潜在的下游候选参与 疾病抑制。 我们建议研究AA抑制外源性IL-27及其下游的机制 调节毛囊免疫反应，预防再生障碍性贫血发生。我们有 采用并进一步发展了一种自发的AA小鼠模型，以在可诱导的、 通过过继转移激活的致病T细胞来控制和特征良好的方式。结合我们的 使用新开发的遗传工具建立的AA模型将使我们能够剖析IL-27可能通过哪些机制 用于消融再生障碍性贫血的发病机制，并有可能揭示新的治疗策略。